| Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 20374310 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: In order to investigate the histological change in effect attenuation cases of etanercept compared with methotrexate (MTX), we performed immunohistochemical examination by seven different molecules. METHODS: We histologically assessed synovial tissue from five MTX-treated rheumatoid arthritis (RA) patients as control and six etanercept and MTX-treated RA patients after synovectomy by arthroscopy. The synovium of both groups were assessed by hematoxylin and eosin (HE) and we also analysed the expression of tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), matrix metalloproteinase-3 (MMP-3), B-cell precursors and mature B-cell transmembrane protein, CD20, macrophage marker, CD68, bromodeoxyuridine (BrdU) and vascular endothelial growth factor (VEGF) by immunohistochemistry. RESULTS: HE staining showed vascular and cell proliferations of the synovium of the RA patients who received etanercept compared with the control MTX group. TNF-alpha and IL-6 were expressed in both groups.MMP-3 and CD68 expressed less significantly in the etanercept group compared with the control (P < 0.05). CD20 strongly expressed in the etanercept group significantly (P < 0.05). BrdU expressed in the synovium in the etanercept group significantly (P < 0.05). VEGF was not found overall in both group. CONCLUSION: Based on the histological change of synovium, treatment by etanercept may be involved in vascular and cell proliferations with inhibition of the expression of CD68 and MMP-3 in synovium of RA patients. These findings indicate immunohistochemical change of synovium with etanercept is one of the mechanism of efficacy of etanercept. |
| | |
Authors:
|
Yutaka Suzuki; Kazuhiko Inoue; Junji Chiba; Yasuo Inoue; Katsuaki Kanbe |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: International journal of rheumatic diseases Volume: 12 ISSN: 1756-185X ISO Abbreviation: Int J Rheum Dis Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2010-04-08 Completed Date: 2010-06-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101474930 Medline TA: Int J Rheum Dis Country: England |
Other Details:
|
Languages: eng Pagination: 7-13 Citation Subset: IM |
Affiliation:
|
Department of Orthopaedic Surgery, Tokyo Women's Medical University, Medical Center East, 2-1-10 Nishiogu, Arakawa, Tokyo 116-8567, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antigens, CD / metabolism Antigens, Differentiation, Myelomonocytic / metabolism Antirheumatic Agents / therapeutic use* Arthritis, Rheumatoid / drug therapy*, metabolism, pathology Biological Markers / metabolism Female Fluorescent Antibody Technique, Indirect Humans Immunoglobulin G / therapeutic use* Interleukin-6 / metabolism Male Matrix Metalloproteinase 3 / metabolism Methotrexate / therapeutic use* Middle Aged Receptors, Tumor Necrosis Factor / therapeutic use* Synovial Membrane / drug effects*, metabolism, pathology Tumor Necrosis Factor-alpha / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, CD; 0/Antigens, Differentiation, Myelomonocytic; 0/Antirheumatic Agents; 0/Biological Markers; 0/CD68 antigen, human; 0/IL6 protein, human; 0/Immunoglobulin G; 0/Interleukin-6; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein; 59-05-2/Methotrexate; EC 3.4.24.17/Matrix Metalloproteinase 3 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of androgen receptor CAG repeat polymorphism with VO?max response to hypoxic training in...
Next Document: Three years experience with the prescription of anti-TNF-alpha inhibitors at Dr Soliman Fakeeh Hospi...